According to an exploratory analysis of data from the POSEIDON trial, patients with non–small cell lung cancer and KRAS, STK11, or KEAP1 mutations fared better on the three-drug combination of tremelimumab and durvalumab plus chemotherapy compared with chemotherapy alone. However, small sample sizes precluded any definitive interpretation of the findings.

You do not currently have access to this content.